87 related articles for article (PubMed ID: 18202788)
1. DNA methylation and sensitivity to antimetabolites in cancer cell lines.
Sasaki S; Kobunai T; Kitayama J; Nagawa H
Oncol Rep; 2008 Feb; 19(2):407-12. PubMed ID: 18202788
[TBL] [Abstract][Full Text] [Related]
2. Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time.
Sasaki S; Watanabe T; Kobunai T; Nagawa H
Cancer Lett; 2006 Sep; 241(2):256-62. PubMed ID: 16307843
[TBL] [Abstract][Full Text] [Related]
3. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
4. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
5. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
6. Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Kobunai T; Ooyama A; Sasaki S; Wierzba K; Takechi T; Fukushima M; Watanabe T; Nagawa H
Eur J Cancer; 2007 Mar; 43(4):791-8. PubMed ID: 17254767
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
8. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
De Mattia E; Toffoli G
Eur J Cancer; 2009 May; 45(8):1333-51. PubMed ID: 19144510
[TBL] [Abstract][Full Text] [Related]
9. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
10. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
11. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.
Kuang SQ; Ling X; Sanchez-Gonzalez B; Yang H; Andreeff M; Garcia-Manero G
Oncogene; 2007 Mar; 26(10):1439-48. PubMed ID: 16936778
[TBL] [Abstract][Full Text] [Related]
12. Methylenetetrahydrofolate reductase genotype association with the risk of follicular lymphoma.
Ismail SI; Ababneh NA; Khader Y; Abu-Khader AA; Awidi A
Cancer Genet Cytogenet; 2009 Dec; 195(2):120-4. PubMed ID: 19963111
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.
Lu CY; Hsieh SY; Lu YJ; Wu CS; Chen LC; Lo SJ; Wu CT; Chou MY; Huang TH; Chang YS
Genes Chromosomes Cancer; 2009 Dec; 48(12):1057-68. PubMed ID: 19760608
[TBL] [Abstract][Full Text] [Related]
14. Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.
Charasson V; Hillaire-Buys D; Solassol I; Laurand-Quancard A; Pinguet F; Le Morvan V; Robert J
Eur J Cancer; 2009 Sep; 45(13):2391-401. PubMed ID: 19501504
[TBL] [Abstract][Full Text] [Related]
15. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer.
Wanajo A; Sasaki A; Nagasaki H; Shimada S; Otsubo T; Owaki S; Shimizu Y; Eishi Y; Kojima K; Nakajima Y; Kawano T; Yuasa Y; Akiyama Y
Gastroenterology; 2008 Aug; 135(2):580-90. PubMed ID: 18588891
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
19. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
